Shareprice
16 Jan 2025

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide presents today at Orphan Drugs

News


May 27, 2020

Copenhagen, Denmark, May 27, 2020 – FluoGuide presents today as one of eight presenting companies at Orphan Drugs, an event hosted by Redeye.

Today, 27 May at 11:10 (CEST), FluoGuide’s CEO Morten Albrechtsen presents the company and some of the recent developments.  The presentation is live broadcasted and can be followed at https://www.redeye.se/live/orphan-27-maj.  

For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all